<DOC>
	<DOC>NCT01366599</DOC>
	<brief_summary>Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).</brief_summary>
	<brief_title>CV Events in Emetogenic Chemotherapy</brief_title>
	<detailed_description>Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Enrollment in IHCIS in 2006 At least one HEC or MEC claim in 2006 HEC or MEC claim three months before first HEC/MEC claim "washin" period (i.e. must be enrolled for three months prior to first HEC/MEC claim. For patients whose first HEC/MEC event is between January 1,2006 and March 31, 2006, enrollment criteria for inclusion in the study may extend as far back as October 1, 2005) HEC or MEC claims prior to 45 days after last HEC or MEC claim "washout" period. (For patients whose last claim in 2006 was seen after December 1, 2006 enrollment into 2007 to look for further treatment and the 45 day "washout" period will be required.)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>highly emetogenic chemotherapy</keyword>
	<keyword>HEC</keyword>
	<keyword>moderately emetogenic chemotherapy</keyword>
	<keyword>MEC</keyword>
</DOC>